Publication | Closed Access

Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors

Apo2l/trail LigandEnhanced TumorP21 CleavageMedicineApoptosisPharmacologyCell DeathAnti-cancer AgentCancer TreatmentOncologyCell BiologyCancer ResearchTumor Biology